28.10.2020
В. М. Цветов; К. Б. Мирзаев; Д. А. Сычёв
Current and future use of remdesivir in patients with COVID-19
28.10.2020
В. А. Отделенов; Ю. Ю. Киселёв; К. Б. Мирзаев; А. В. Матвеев; Д. А. Сычёв
of hydroxychloroquine, especially if combined with azithromycin, for COVID-19. Such treatment may be associated
28.10.2020
А. В. Крюков; В. А. Отделенов; Д. А. Сычёв
We present anticoagulant outpatient deprescribing algorithm in patients with COVID-19 discharged
28.10.2020
Ю. Ю. Киселёв; А. В. Матвеев; Д. А. Сычёв
There exist some theoretical premises for the use of colchicine in patients with COVID-19
28.10.2020
И. С. Бурашникова; В. М. Цветов; К. Б. Мирзаев; Д. А. Сычёв
Current use of dipyridamole in COVID-19 is mainly based on its antithrombotic activity, since
28.10.2020
К. Б. Мирзаев; Д. А. Сычёв
The use of hydroxychloroquine for COVID-19 treatment and prevention should be restricted in both
28.10.2020
В. А. Отделенов; А. В. Матвеев; Д. А. Сычёв
treatment of “cytokine storm” in severe COVID-19.
28.10.2020
В. А. Отделенов; К. Б. Мирзаев; Д. А. Сычёв
Use of canakinumab in patients with COVID-19 is currently lacking proper evidence base, and should
28.10.2020
И. Н. Сычёв; А. В. Матвеев; Д. А. Сычёв
There is currently no evidence for vitamin D3 effectiveness for COVID-19 treatment and prevention.
28.10.2020
В. М. Цветов; А. В. Матвеев; Д. А. Сычёв
Routine clinical use of olokizumab in COVID-19 is not recommended. The use of olokizumab
